Cyclerion Therapeutics Partners with Medsteer to Advance CYC-126 for Treatment-Resistant Depression
Key Insights
Cyclerion Therapeutics announced an exclusive collaboration with Medsteer (search) to integrate closed-loop anesthetic delivery technology into its lead program CYC-126 (search) for treatment-resistant depression.
CYC-126 (search) is designed as an individualized, precision-delivered treatment that combines anesthetic agents with real-time EEG (search) monitoring and algorithm-guided dosing to target specific brain states.
The company plans to initiate a multinational Phase 2 proof-of-concept study in the second half of 2026, with first patient enrollment expected in Australia.
Cyclerion Therapeutics has entered into an application-specific, exclusive collaboration with Medsteer (search), a leader in anesthetic delivery systems driven by real-time patient feedback, to advance development of CYC-126 (search), a potentially novel anesthetic-based investigational therapy for treatment-resistant depression (TRD). The strategic partnership expands upon the companies' existing development collaboration and aims to integrate Medsteer's proprietary technology into Cyclerion's lead neuropsychiatric program.
Novel Approach to Treatment-Resistant Depression
CYC-126 (search) represents a potentially first-in-class therapy that incorporates real-time patient feedback for treating TRD, a condition that remains one of the most pressing unmet needs in mental health. The investigational treatment is being designed as an individualized, precision-delivered approach that leverages well-characterized anesthetic agents in combination with real-time EEG (search) monitoring and algorithm-guided dosing.
According to Regina Graul, Ph.D., Chief Executive Officer of Cyclerion, "This approach has the potential to enable clinicians to more precisely guide patients toward targeted brain states that may be associated with antidepressant effects, addressing a significant unmet need among patients with TRD who are looking for alternative therapies."
Strategic Collaboration Details
The collaboration provides Cyclerion with access to Medsteer (search)'s validated EEG (search)-guided closed-loop control technology, including computational control modules, control software, and extensive annotated datasets. Medsteer's technology is supported by experienced engineering capabilities developed across more than 25 clinical settings and more than 9,000 patients.
"Medsteer (search)'s deep translational expertise and proven closed-loop anesthetic delivery technology make them an ideal strategic partner to accelerate our anesthesia-enabled platform development while potentially reducing technical and execution risk," said Graul.
Nicolas Choussat, co-founder and Chief Operating Officer of Medsteer (search), emphasized the potential of their technology integration: "Integrating intelligent software agents with real-time patient feedback holds great potential to improve clinical outcomes. We are thrilled to ramp up our work with Cyclerion Therapeutics in the field of neuropsychiatry and leverage our proprietary algorithms to help build the next generation of therapies."
Development Timeline and Regulatory Strategy
Following the strategic collaboration announcement, Cyclerion remains on track to complete device integration and finalize its proprietary drug delivery system ahead of the planned Phase 2 proof-of-concept study initiation in the second half of 2026. The company expects to leverage primarily FDA-cleared device components, together with the Medsteer (search) strategic partnership and a previously announced MIT license, with the company's own fit-for-purpose improvements.
Cyclerion is advancing its regulatory strategy to support initiation of a multinational Phase 2 proof-of-concept clinical trial. The company currently plans to target first patient enrollment in Australia in 2026 under the CTN/HREC (Clinical Trial Notification / Human Research Ethics Committee) pathway, which provides for an expedited review process, while continuing preparatory work to support a potential future U.S. IND submission. Initial proof-of-concept clinical data from this program are currently expected in 2027.
Technology Platform and Market Opportunity
The collaboration extends beyond neuropsychiatric diseases such as TRD to other applications, excluding use in major surgery, intensive care units, or within the context of medical transport. Medsteer (search)'s EasyTIVA regulation algorithm automates the delivery of propofol and remifentanil for medical procedures and has been clinically validated through extensive patient experience.
The partnership represents a significant step in Cyclerion's strategic shift toward neuropsychiatry. The Cambridge, Massachusetts-based biopharmaceutical company became an independent, publicly traded entity in 2019 following a spin-off from Ironwood Pharmaceuticals and has since focused on building a new pipeline of therapeutics for neuropsychiatric diseases.
Expert Perspective
The development will be discussed during an investor webcast featuring Dr. Husseini Manji, a globally recognized leader in neuroscience and mental health innovation. Dr. Manji's distinguished career spans leadership roles at the National Institutes of Health and Janssen/Johnson & Johnson, where he served as Global Head of Neuroscience. He currently holds professorships at Oxford University and Yale University and is a member of the National Academy of Medicine.